Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

10.20USD
26 May 2017
Change (% chg)

$-0.19 (-1.83%)
Prev Close
$10.39
Open
$10.31
Day's High
$10.44
Day's Low
$10.02
Volume
575,054
Avg. Vol
437,063
52-wk High
$27.00
52-wk Low
$9.50

DEPO.OQ

Chart for DEPO.OQ

About

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac... (more)

Overall

Beta: 1.18
Market Cap(Mil.): $635.88
Shares Outstanding(Mil.): 62.34
Dividend: --
Yield (%): --

Financials

  DEPO.OQ Industry Sector
P/E (TTM): -- 14.27 17.41
EPS (TTM): -1.53 -- --
ROI: -9.93 -7.17 -5.42
ROE: -35.68 -6.63 -4.68

BRIEF-Depomed announces corporate governance updates

* Depomed - revised each of charters of audit committee, compensation committee, nominating and corporate governance committee

May 22 2017

BRIEF-Depomed reports Q1 adjusted non-GAAP earnings $0.07/shr

* Depomed announces first quarter 2017 financial results and strategic initiatives aimed at driving sustainable long-term growth and shareholder value

May 09 2017

BRIEF-Depomed announces prepayment of $100 mln of secured debt facility

* Depomed announces prepayment of $100 million of secured debt facility

Apr 04 2017

BRIEF-Depomed- Cooperation agreement with Starboard Value LP includes standstill commitments by Starboard

* Depomed- cooperation agreement with Starboard Value LP includes standstill commitments by Starboard

Mar 29 2017

U.S. senator launches probe into five top opioid drugmakers

U.S. Democratic Senator Claire McCaskill sought on Tuesday details from the nation's top opioid drugmakers on their sales and marketing practices, as lawmakers step up efforts to tackle the country's deadly opioid crisis.

Mar 28 2017

Depomed names new CEO, directors in deal with activist Starboard

Depomed Inc reached a deal with activist investor Starboard Value LP to name a new chief executive officer and two other directors to its board.

Mar 28 2017

Depomed names new CEO

March 28 Drugmaker Depomed Inc, which has been facing pressure from activist investor Starboard Value LP, named a new chief executive officer and said it would add three new directors to its board.

Mar 28 2017

BRIEF-Depomed announces cooperation agreement with Starboard Value Lp

* Depomed announces cooperation agreement with Starboard Value Lp including CEO and board changes

Mar 28 2017

BRIEF-Depomed reports Q4 loss per share $0.72

* Depomed reports fourth quarter and full year 2016 financial results

Feb 21 2017

More From Around the Web

Earnings vs. Estimates